SNPSSynopsys
Synopsys, Inc. (Synopsys, we, our or us) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. 10-K, Item 1
Deals between SNPS and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement. Below: what the proxy filed 2026-02-19 reports that the one filed 2025-02-14 did not, quoted as filed.
New this year
2 newParagraphs about a deal, a person or a relative with nothing like them in the proxy filed 2025-02-14.
Transactions with Related Persons“In connection with the closing of Synopsys' acquisition of Ansys, Synopsys entered into a Termination Notice and Separation Agreement and General Release dated July 17, 2025 (the Separation Agreement) with Dr. Ajei Gopal, a current director of Synopsys. Pursuant to the Separation Agreement, Dr. Gopal received certain compensation and benefits, as detailed in footnote 10 of the Director Compensation table on page 39. The compensation and benefits payable to Dr. Gopal in connection with his Separation Agreement were in accordance with Dr. Gopal’s severance entitlements pursuant to his employment agreement with Ansys.”
Read it in the proxy ↗
Transactions with Related Persons“From the beginning of fiscal 2025 until the present, there have been no (and there are no currently proposed) transactions involving an amount in excess of $120,000 in which Synopsys was (or is to be) a participant and any executive officer, director, five percent beneficial owner of our common stock or member of the immediate family of any of the foregoing persons had (or will have) a direct or indirect material interest, except the compensation arrangements described in this Proxy Statement for our NEOs and directors and the Separation Agreement described above.”
Read it in the proxy ↗
The whole section 6 paragraphs, proxy filed 2026-02-19
Transactions with Related Persons“Pursuant to its charter, the Audit Committee reviews and approves or ratifies all related party transactions as required by the Nasdaq Listing Standards or as otherwise required to be disclosed in Synopsys’ financial statements or periodic filings with the SEC, and in accordance with Synopsys’ Related-Person Transactions Policy. Related party transactions include, among other things, transactions between us, our executive officers and directors, beneficial owners of five percent or greater of our securities, and all other related persons specified under Item 404 of Regulation S-K promulgated by the SEC. We have adopted written policies and procedures regarding the identification of related parties and transactions, and the approval process for such transactions. The Audit Committee will consider each proposed transaction in light of the specific facts and circumstances presented, including but not limited to the risks, costs, and benefits to us and the availability from other sources of comparable products or services.”
Read it in the proxy ↗
Transactions with Related Persons“In connection with the closing of Synopsys' acquisition of Ansys, Synopsys entered into a Termination Notice and Separation Agreement and General Release dated July 17, 2025 (the Separation Agreement) with Dr. Ajei Gopal, a current director of Synopsys. Pursuant to the Separation Agreement, Dr. Gopal received certain compensation and benefits, as detailed in footnote 10 of the Director Compensation table on page 39. The compensation and benefits payable to Dr. Gopal in connection with his Separation Agreement were in accordance with Dr. Gopal’s severance entitlements pursuant to his employment agreement with Ansys.”
Read it in the proxy ↗
Transactions with Related Persons“From the beginning of fiscal 2025 until the present, there have been no (and there are no currently proposed) transactions involving an amount in excess of $120,000 in which Synopsys was (or is to be) a participant and any executive officer, director, five percent beneficial owner of our common stock or member of the immediate family of any of the foregoing persons had (or will have) a direct or indirect material interest, except the compensation arrangements described in this Proxy Statement for our NEOs and directors and the Separation Agreement described above.”
Read it in the proxy ↗
Our Overboarding Policy“The Governance Committee considers each director’s ability to dedicate sufficient time, energy and attention to the fulfillment of their duties when it nominates directors each year and when identifying leadership positions on our Board, including committee chairs. Our Corporate Governance Guidelines state that a director who is an executive officer of a public company may serve on the board of no more than three public companies, including their directorship on our Board, while all other independent directors may serve on up to four public company boards in total, including their directorship on our Board.”
Read it in the proxy ↗
Our Overboarding Policy“All of our director nominees are in compliance with our overboarding policy as of the Record Date.”
Read it in the proxy ↗
Overboarding Policy“(1) Dr. de Geus, Mr. Ghazi and Mr. Painter hold positions as public company executives. Dr. de Geus is our Executive Chair and Mr. Ghazi is our President and Chief Executive Officer. Mr. Painter is the president and chief executive officer of Trimble Inc.”
Read it in the proxy ↗
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Work on SNPS in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/SNPS/export.csv") into a cell.